Home » Authors » Cynthia Robbins-Roth

Articles by Cynthia Robbins-Roth

Biotechnology Soap Opera: FDA, Sex, Politics, Religion

June 5, 2006

By Cynthia Robbins-Roth

High-Priced Drugs Causing Angst; Genzyme Stands Pat

May 22, 2006

By Cynthia Robbins-Roth

High-Priced Drugs Causing Angst; Genzyme Stands Pat

May 22, 2006

By Cynthia Robbins-Roth

How Frustrated Firm ReqMed Created New Biotech Strategy

May 8, 2006

By Cynthia Robbins-Roth

How Frustrated Firm ReqMed Created New Biotech Strategy

May 8, 2006

By Cynthia Robbins-Roth

How Juvaris Found New Path, Gathered Funds, Moved Ahead

April 24, 2006

By Cynthia Robbins-Roth

How Juvaris Found New Path, Gathered Funds, Moved Ahead

April 24, 2006

By Cynthia Robbins-Roth

Four Points Of Concern As Biotechnology Grows

April 10, 2006

By Cynthia Robbins-Roth

Four Points Of Concern As Biotechnology Grows

April 10, 2006

By Cynthia Robbins-Roth

Need Public Market Access? Go Knock On Heaven’s Door (Corp.)

March 27, 2006

By Cynthia Robbins-Roth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...